怀孕的苏丹妇女的甲状腺功能和胰岛素抵抗
Wisal Abbas1, Abdelmageed Elmugabil2, Duria A Rayis3
1Faculty of Medicine, Kordofan University, Elobeid, Sudan.
BMC endocrine disorders
|September 28, 2024
概括
甲状腺激素影响葡萄糖代谢. 这项研究发现,在孕妇中,自由三甲状腺素 (FT3) 与胰岛素耐药性 (IR) 有正相关,而自由甲状腺素 (FT4) 与胰岛素耐药性有负相关.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 怀孕研究 怀孕研究
背景情况:
- 甲状腺功能测试,包括自由三甲状腺素 (FT3),自由甲状腺素 (FT4) 和甲状腺刺激激素 (TSH),对于葡萄糖平衡和胰岛素平衡至关重要.
- 甲状腺功能障碍会破坏葡萄糖代谢,导致胰岛素抵抗 (IR).
研究的目的:
- 调查怀孕的苏丹妇女甲状腺功能参数和胰岛素抵抗 (IR) 之间的关联.
主要方法:
- 一项涉及127名孕妇的横截面研究在苏丹喀土穆进行.
- 通过问卷收集产科/社会人口统计学特征的数据.
- 测量了TSH,FT3,FT4,空腹血葡萄糖 (FPG) 和空腹胰岛素的血清水平. 胰岛素耐药性的计算是使用对胰岛素耐药性 (HOMA-IR) 方程的同居模式评估.
主要成果:
- 在HOMA-IR和FT3水平之间观察到显著的正相关性 (r=0.375,P<0.001).
- 相反,在HOMA-IR和FT4水平之间发现了显著的负相关性 (r=-0.312,P<0.001).
- 禁食胰岛素水平也与FT3呈正相关 (r=0.438,P<0.001),与FT4呈负相关 (r=-0.305,P<0.001).
结论:
- 在没有甲状腺功能障碍的健康孕妇中,FT3与HOMA-IR呈现正相关性,而FT4显示负相关性.
- 这些发现表明,有必要对怀孕妇女进行甲状腺功能障碍和胰岛素耐药性查.
- 需要进一步的研究来阐明这些关系.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Pathophysiology of Diabetes
894
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
894
Oral Hypoglycemic Agents: Biguanides and Glitazones
181
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
181
Oral Hypoglycemic Agents: Sulfonylureas
195
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
195
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Insulin: Dosing Regimen and Adverse Effects
155
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
155


